Darell Bigner
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Darell Bigner sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Darell Bigner: 6 sponsored US clinical trials, 4 recruiting.
Darell Bigner sponsors 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Newly Diagnosed MGMT Unmethylated Glioblastoma, with 1 trials.
Upper-quartile sponsor footprint
Darell Bigner sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
NCT06455605
Lerapolturev (PVSRIPO) in GBM
NCT06177964
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
NCT05734560
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
NCT04547777
D2C7-IT With Atezolizumab for Recurrent Gliomas
NCT04160494
D2C7 for Adult Patients With Recurrent Malignant Glioma
NCT02303678
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
What is open in the Darell Bigner pipeline
4 recruiting of 6 indexed (67% open); 1 completed (17%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Newly Diagnosed MGMT Unmethylated Glioblastoma (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Darell Bigner: open-pipeline peers nationwide
Peers matched on 6 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
Darell Bigner sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
- Alexander B Olawaiye, MD · 67% recruiting · 3 trials
Related
What to do with this Darell Bigner page
6 registered trials is a research-attention snapshot, not an endorsement of Darell Bigner or any single study.
- 4 of Darell Bigner's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Newly Diagnosed MGMT Unmethylated Glioblastoma is the condition Darell Bigner studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Newly Diagnosed MGMT Unmethylated Glioblastoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Darell Bigner pipeline card: 6 registered trials from official public datasets.Report a data error.